Business
Medison Disappointed that Knight Therapeutics has Resorted to Blatant Misrepresentations to Avoid Scrutiny
Medison Disappointed that Knight Therapeutics has Resorted to Blatant Misrepresentations t...
About this update from Knight Therapeutics, Inc.
[{"type":"text","content":"\n\n\n\nMedison Disappointed that Knight Therapeutics has Resorted to Blatant Misrepresentations to Avoid Scrutiny\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen3{\nBORDER-TOP:1pt; BORDER-RIGHT:1pt; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM:1pt; PADDING-LEFT:0.50em; BORDER-LEFT:1pt; PADDING-RIGHT:0.50em\n}\n.prngen5{\nBORDER-TOP:1pt; BORDER-RIGHT:1pt; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM:black 1pt dotted; PADDING-LEFT:0.50em; BORDER-LEFT:1pt; PADDING-RIGHT:0.50em\n}\n.prngen4{\nBORDER-TOP:1pt; BORDER-RIGHT:1pt; VERTICAL-ALIGN: MIDDLE; BORDER-BOTTOM:black 1pt dotted; TEXT-ALIGN: CENTER; PADDING-LEFT:0.50em; BORDER-LEFT:1pt; PADDING-RIGHT:0.50em\n}\n.prngen2{\nBORDER-TOP:1pt; BORDER-RIGHT:1pt; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM:black 1pt solid; TEXT-ALIGN: CENTER; PADDING-LEFT:0.50em; BORDER-LEFT:1pt; PADDING-RIGHT:0.50em\n}\n.prnvam{\nVERTICAL-ALIGN: MIDDLE\n}\n.prnsbb1{\nBORDER-BOTTOM:1pt\n}\n.prnsbr1{\nBORDER-RIGHT:1pt\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n.prnpl6{\nPADDING-LEFT:0.50em\n}\n.prnsbt1{\nBORDER-TOP:1pt\n}\n.prnml6{\nMARGIN-LEFT:0.50em; MARGIN-TOP:0em; MARGIN-BOTTOM:0em\n}\n.prnpr6{\nPADDING-RIGHT:0.50em\n}\n.prntblns{\nBORDER-TOP: 1pt; BORDER-RIGHT: 1pt; BORDER-COLLAPSE: collapse; BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt\n}\n.prnsbl1{\nBORDER-LEFT:1pt\n}\n\n\n\n\n\n\n\nCanada NewsWire\nPETACH TIKVA, Israel, April 10, 2019\n\n\n\nKnight is a failure, with a floundering share price and minimal progress at building an operating business Apparently unable to respond to Medison's criticisms on the merits, Knight has wasted corporate assets and harassed Medison with spurious litigation, demanded thousands of documents, and has mounted a dishonest and hypocritical proxy campaign defense Medison urges Knight shareholders to remain focused on the fact that Knight's stock has produced no returns for shareholders for more than three years and implies little or no value for Knight's operating business Medison encourages shareholders to vote for five new independent nominees, in addition to Meir Jakobsohn, to bring objective oversight and an actionable strategic plan PETACH TIK...